Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Gynecological Endocrinology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/09513599809029344PMID 3067545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study

  2007cited by this paper
• One year's treatment of paget's disease of bone by synthetic salmon calcitonin as a nasal spray

  1988cited by this paper
• 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.

  1987cited by this paper
• Long-term follow-up observations on treatment in Paget's disease of bone.

  1987cited by this paper
• Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects.

  1987cited by this paper
• Secretion and metabolism of monomeric human calcitonin: Effects of age, sex, and thyroid damage

  1986cited by this paper
• The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis

  1986cited by this paper
• Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis

  1985cited by this paper
• Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection.

  1985cited by this paper
• Calcitonin levels in normal subjects according to age and sex.

  1984cited by this paper
• The effect of estrogen dose on postmenopausal bone loss.

  1984cited by this paper
• Intranasal glucagon raises blood glucose concentrations in healthy volunteers.

  1983cited by this paper
• Regulation of calcium‐regulating hormones by exogenous sex steroids in early postmenopause

  1983cited by this paper
• An estimate of the endogenous secretion rate of calcitonin in man.

  1982cited by this paper
• Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects.

  1982cited by this paper
• Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.

  1980cited by this paper
• Prevention of spinal osteoporosis in oophorectomised women.

  1980cited by this paper
• FUNCTIONAL SIGNIFICANCE OF ANTIBODY FORMATION AFTER LONG‐TERM SALMON CALCITONIN THERAPY

  1979cited by this paper
• Relative deficiency of plasma-calcitonin in normal women.

  1978cited by this paper
• Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment.

  1974cited by this paper
• Effectiveness of parathyroid hormone, calcitonin and phosphate on bone cells in Paget's disease.

  1974cited by this paper
• Treatment of Paget's disease of bone with synthetic human calcitonin: biochemical and roentgenologic changes.

  1974cited by this paper
• Comparison of plasma levels of luteinizing hormone releasing hormone in men after intravenous or intranasal administration.

  1974cited by this paper
• Effects of calcitonin on osteoclasts in vivo

  1973cited by this paper
• An evaluation of antibodies and clinical resistance to salmon calcitonin.

  1972cited by this paper
• Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal females

  1971cited by this paper
• Amino acid sequence of salmon ultimobranchial calcitonin.

  1969cited by this paper
• Evidence for calcitonin--a new hormone from the parathyroid that lowers blood calcium.

  1962cited by this paper

• Peptide and Protein Hormones

  2000cites this paper
• Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis

  1996cites this paper
• Effectiveness and safety of medium- and long-term elcatonin use in the prevention and treatment of bone mass loss

  1995cites this paper
• Prevention of osteoporosis with nasal salmon calcitonin: Effect of anti-salmon calcitonin antibody formation

  1993cites this paper
• Bone Mineral Metabolism at the Menopause: Determinants and Markers

  1993cites this paper
• Postmenopausal osteoporosis: prevention and treatment with calcitonin.

  1992cites this paper
• Salmon calcitonin prevents cyclosporin-A-induced high turnover bone loss.

  1991cites this paper
• Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

  1991cites this paper
• Intranasal Salmon Calcitonin

  1991cites this paper
• The Effects of Intranasal Salmon Calcitonin on Bone Metabolism in Women with Premature Menopause

  1990cites this paper
• International Standards for salmon calcitonin, eel calcitonin, and the Asu1-7 analogue of eel calcitonin: calibration by international collaborative study.

  1990cites this paper